Portable, contrast-free MRI at the bedside solves a real infrastructure problem in acute stroke care: minutes matter, and fixed scanners aren't always reachable in time. Regulatory and investor momentum (breakthrough-track ambitions, a $9.75M oversubscribed round) suggest the market agrees the timing is right, even with clinical validation still in progress.